BioMarin Pharmaceutical traded at $84.98 this Friday July 1st, increasing $2.11 or 2.55 percent since the previous trading session. Looking back, over the last four weeks, BioMarin Pharmaceutical gained 12.26 percent. Over the last 12 months, its price fell by 0.57 percent. Looking ahead, we forecast BioMarin Pharmaceutical to be priced at 82.68 by the end of this quarter and at 76.14 in one year, according to Trading Economics global macro models projections and analysts expectations.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Acadia Pharmaceuticals 14.37 0.28 1.99% -40.86%
Acorda Therapeutics 0.48 0.01 3.20% -89.34%
Agios Pharmaceuticals 23.36 1.19 5.37% -58.08%
Alnylam Pharmaceuticals 148.25 2.40 1.65% -13.52%
Amgen 245.55 2.25 0.92% -1.27%
Bayer 57.24 -0.11 -0.19% 11.30%
Biogen 210.63 6.69 3.28% -39.60%
Bluebird Bio 4.28 0.14 3.38% -86.36%
BioMarin Pharmaceutical 84.98 2.11 2.55% -0.57%
Gilead Sciences 62.36 0.55 0.89% -10.01%
Intercept Pharmaceuticals 14.13 0.32 2.32% -29.31%
Incyte Corp 77.67 1.70 2.24% -7.07%
Insmed 20.89 1.17 5.93% -26.70%
Ionis Pharmaceuticals 38.06 1.04 2.81% -4.66%
Moderna Inc 149.95 7.10 4.97% -36.00%
Neurocrine Biosciences 99.25 1.77 1.82% 0.65%
Puma Biotechnology 2.78 -0.07 -2.46% -68.48%
PTC Therapeutics 41.85 1.79 4.47% -2.88%
Ultragenyx Pharmaceutical 62.65 2.99 5.01% -33.50%
Regeneron Pharmaceuticals 595.40 4.27 0.72% 2.01%
Roche Holding 322.10 1.70 0.53% -8.06%
Seattle Genetics 180.11 3.17 1.79% 14.52%
Sangamo BioSciences 4.28 0.14 3.38% -63.45%
Sanofi 51.01 0.98 1.96% -2.60%
Sarepta Therapeutics 75.71 0.75 1.00% 0.62%
United Therapeutics 238.00 2.36 1.00% 29.12%
Vertex Pharmaceuticals 287.32 5.53 1.96% 43.27%

Indexes Price Day Year
USND 11128 99.11 0.90% -23.99%

BioMarin Pharmaceutical
BioMarin Pharmaceutical Inc. is a biotechnology company. The Company develops and commercializes pharmaceuticals for various diseases and medical conditions. As of December 31, 2016, the Company's therapy portfolio consisted of five products, and multiple clinical and pre-clinical product candidates. Its commercial products include Aldurazyme (laronidase) for Mucopolysaccharidosis I (MPS I), Firdapse (amifampridine phosphate) for Lambert Eaton Myasthenic Syndrome (LEMS), Kuvan (sapropterin dihydrochloride) for phenylketonuria (PKU), Naglazyme (galsulfase) for Mucopolysaccharidosis VI (MPS VI) and Vimizim (elosulfase alpha) for Mucopolysaccharidosis IV Type A (MPS IV A). The Company is conducting clinical trials on various product candidates for the treatment of various diseases. Its clinical product candidates include Brineura, pegvaliase, vosoritide, BMN 270 and BMN 250.